.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA09_Bendamustine.Bendamustine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA09_Bendamustine.Bendamustine| name: | Bendamustine | |
| ATC code: | L01AA09 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 120 | mg |
| volume of distribution: | 20.3 | L |
| clearance: | 639 | mL/min |
| other parameters in model implementation | ||
Bendamustine is an alkylating antineoplastic agent used primarily in the treatment of hematological malignancies such as chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma (NHL), and multiple myeloma. It is administered intravenously, and is approved for medical use in many countries.
Pharmacokinetic parameters reported in adult patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma after intravenous infusion.
Darwish, M, et al., & Chovan, JP (2015). Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer chemotherapy and pharmacology 75(6) 1143–1154. DOI:10.1007/s00280-015-2727-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25829094
Kim, T, et al., & Yang, DH (2018). Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). BMC cancer 18(1) 729–None. DOI:10.1186/s12885-018-4632-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/29986691